文献速递哮喘慢阻肺

CD131拮抗可阻断生命早期起源的哮喘-慢阻肺重叠小鼠模型中的炎症、肺气肿和纤维化

CD131 antagonism blocks inflammation, emphysema and fibrosis in an asthma-COPD overlap mouse model originating in early life.
PubMed 文献 · Respirology · 2025-01-15

本研究在生命早期建立的双重打击哮喘-慢阻肺重叠(ACO)小鼠模型中,评估靶向CD131(IL-3、IL-5和GM-CSF共享受体亚基)的治疗潜力。结果显示,CD131阻断可减轻肺部炎症,预防气道高反应性、气道纤维化和肺气肿,并防止鼻病毒诱导的急性加重而不影响病毒清除。

要点

  • CD131阻断可减轻ACO小鼠模型的混合粒细胞性炎症。
  • CD131拮抗预防气道高反应性、气道纤维化和肺气肿。
  • CD131阻断防止RV1b诱导的哮喘急性加重且不影响病毒清除。

核心结论

  • CD131信号协调驱动ACO气道炎症和肺重塑的多条病理通路,CD131拮抗是应对ACO复杂免疫病理的新方法。

研究设计与样本

  • 采用屋尘螨(HDM)致敏建立哮喘模型联合弹性蛋白酶处理建立肺气肿模型,构建ACO双打击小鼠模型。
  • 另用人类鼻病毒1b(RV1b)诱导急性哮喘加重模型。
  • 体内使用抗CD131中和抗体阻断CD131信号。

主要发现

  • HDM和弹性蛋白酶暴露小鼠出现气道高反应性(AHR)和肺气肿等哮喘和COPD核心特征。
  • 肺部呈现混合粒细胞性炎症,包括单核细胞来源巨噬细胞、中性粒细胞和嗜酸性粒细胞扩增。
  • RT-qPCR检测到Mmp12、Il5和Il13基因表达升高。
  • 转录组分析显示2型炎症和巨噬细胞活化通路富集。
  • CD131阻断有效减少肺部炎症,预防AHR、气道纤维化和肺气肿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Asthma-COPD overlap (ACO) is characterized by patients exhibiting features of both asthma and COPD. Currently, there is no specific treatment for ACO. This study aimed to investigate the therapeutic potential of targeting CD131, a shared receptor subunit for IL-3, IL-5 and GM-CSF, in ACO development and in preventing acute viral exacerbations. METHODS: A two-hit mouse model of ACO was established by house dust mite (HDM) allergen sensitization to model asthma, and elastase treatment to model emphysema. In a separate model, human rhinovirus 1b (RV1b) was used to induce an acute asthma exacerbation. A neutralizing antibody against CD131 was used to block CD131 in vivo signalling. RESULTS: Mice exposed to HDM and elastase developed cardinal features for asthma and COPD, including airway hyperreactivity (AHR) and emphysema. A mixed granulocytic inflammatory profile was identified in the lungs, including expansion of monocyte-derived macrophages, neutrophils and eosinophils. RT-qPCR analysis detected heightened gene expression of Mmp12, Il5 and Il13. Transcriptomic analysis further revealed pathway enrichment for type 2 inflammation and macrophage activation. Blockade of CD131 effectively reduced the lung inflammation and prevented the development of AHR, airway fibrosis and emphysema. Interestingly, pathway enrichment for Th1 response and interferon production detected in the model was not affected by the treatment. Consistently, CD131 antagonism prevented RV1b-induced asthma exacerbation without compromising RV1b clearance. CONCLUSION: CD131 signalling coordinates multiple pathological pathways that drive airway inflammation and lung remodelling in ACO. Hence, CD131 antagonism represents a novel approach to combating the immunopathology in the complex ACO setting.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Wang, Fung, Aloe, et al. CD131 antagonism blocks inflammation, emphysema and fibrosis in an asthma-COPD overlap mouse model originating in early life. Respirology. 2025. PMID: 39814691. doi:10.1111/resp.14877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。